The role of interleukin-1 in allergy-related disorders

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 5, 2012, Pages 477-484

  Krause, Karoline ^a   Metz, Martin ^a   Makris, Michael ^a,b   Zuberbier, Torsten ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

allergy; inflammasome; interleukin 1; urticaria

Indexed keywords

CRYOPYRIN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2 RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; VIRUS DNA; VIRUS RNA;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADAPTIVE IMMUNITY; ADULT ONSET STILL DISEASE; ALLERGIC DISEASE; ANTIBODY PRODUCTION; ASTHMA; ATHEROSCLEROSIS; ATOPIC DERMATITIS; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; BEHCET DISEASE; BLAU SYNDROME; CELL DIFFERENTIATION; CELL SURVIVAL; CINCA SYNDROME; CLINICAL FEATURE; CONTACT ALLERGY; CONTACT DERMATITIS; CROHN DISEASE; CYTOKINE RELEASE; DISEASE EXACERBATION; FAMILIAL MEDITERRANEAN FEVER; GAIN OF FUNCTION MUTATION; GOUT; HEADACHE; HEREDITARY PERIODIC FEVER; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFLAMMATION; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; LANGERHANS CELL; LYMPHOCYTE PROLIFERATION; MAJEED SYNDROME; MALAISE; MAST CELL; MIGRATION; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAPA SYNDROME; PRIORITY JOURNAL; RECURRENT FEVER; REMISSION; REVIEW; SAPHO SYNDROME; SCHNITZLER SYNDROME; TH17 CELL; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; URTICARIA;

ANIMALS; ASTHMA; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; MICE; URTICARIA;

EID: 84865999935     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283574d0c     Document Type: Review

References (62)

1. Gery I, Gershon RK, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med 1972; 136:128-142.
2. Gery I, Waksman BH. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med 1972; 136:143-155.
3. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A 1977; 74:4624-4627.
4. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-550.
5. Nemunaitis J, Ross M, Meisenberg B, et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant 1994; 14:583-588.
6. Vadhan-Raj S, Kudelka AP, Garrison L, et al. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994; 12:707-714.
7. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147.
8. Hsu LC, Ali SR, McGillivray S, et al. A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A 2008; 105:7803-7808.
9. Gross O, Poeck H, Bscheider M, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for antifungal host defence. Nature 2009; 459:433-436.
10. Kanneganti TD, Body-Malapel M, Amer A, et al. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and doublestranded RNA. J Biol Chem 2006; 281:36560-36568.
11. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011; 166:1-15.
12. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581-592.
13. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Antiinterleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011; 38:516-518.
14. Kontzias A, Efthimiou P. The use of canakinumab, a novel IL-1beta longacting inhibitor, in refractory adult-onset still's disease. Semin Arthritis Rheum 2012.
15. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011; 70:747-754.
16. Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64:876-884.
17. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110:851-860.
18. Okamoto M, Liu W, Luo Y, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2010; 285:6477-6488.
19. Nakamura Y, Kambe N, Saito M, et al. Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamineindependent urticaria. J Exp Med 2009; 206:1037-1046.
20. Birrell MA, Eltom S. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther 2011; 130:364-370.
21. Watanabe H, Gaide O, Petrilli V, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol 2007; 127:1956-1963.
22. Dai X, Sayama K, Tohyama M, et al. Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes. J Allergy Clin Immunol 2011; 127:806-814; e801-e804.
23. Lamkanfi M, Walle LV, Kanneganti TD. Deregulated inflammasome signaling in disease. Immunol Rev 2011; 243:163-173.
24. Guarda G, Zenger M, Yazdi AS, et al. Differential expression of NLRP3 among hematopoietic cells. J Immunol 2011; 186:2529-2534.
25. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-426.
26. Muruve DA, Petrilli V, Zaiss AK, et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452:103-107.
27. McNeela EA, Burke A, Neill DR, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog 2010; 6:e1001191.
28. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241.
29. Duncan JA, Bergstralh DT, Wang Y, et al. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci U S A 2007; 104:8041-8046.
30. Yazdi AS, Guarda G, Riteau N, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1alpha and IL-1beta. Proc Natl Acad Sci U S A 2010; 107:19449-19454.
31. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-305.
32. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17:25-31.
33. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22:178-181.
34. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426-2437.
35. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010; 140:784-790.
36. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-144.
37. Dinarello CA. A clinical perspective of IL-1beta as the gatekeeper of inflammation. Eur J Immunol 2011; 41:1203-1217.
38. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006; 3:e297.
39. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64:1417-1426.
40. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443-2452.
41. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-2425.
42. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70:2095-2102.
43. Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011; 13:R202.
44. Pizzirani C, Falzoni S, Govoni M, et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009; 48:1304-1308.
45. Volz T, Wolbing F, Fischer J, et al. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Acta Derm Venereol 2012.
46. de Koning HD, Bodar EJ, van der Meer JW, Simon A. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 2007; 37:137-148.
47. Krause K, Weller K, Stefaniak R, et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy (in press).
48. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber I. Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 2005; 32:67-70.
49. Weber FC, Esser PR, Muller T, et al. Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med 2010; 207:2609-2619.
50. Kish DD, Gorbachev AV, Fairchild RL. IL-1 receptor signaling is required at multiple stages of sensitization and elicitation of the contact hypersensitivity response. J Immunol 2012; 188:1761-1771.
51. Kondo S, Pastore S, Fujisawa H, et al. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995; 105:334-338.
52. Feldmeyer L, Keller M, Niklaus G, et al. The inflammasome mediates UVBinduced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol 2007; 17:1140-1145.
53. Maintz L, Novak N. Modifications of the innate immune system in atopic dermatitis. J Innate Immun 2011; 3:131-141.
54. Munoz-Planillo R, Franchi L, Miller LS, Nunez G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J Immunol 2009; 183:3942-3948.
55. Nakae S, Komiyama Y, Yokoyama H, et al. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol 2003; 15:483-490.
56. Schmitz N, Kurrer M, Kopf M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 2003; 33:991-1000.
57. Besnard AG, Guillou N, Tschopp J, et al. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 2011; 66:1047-1057.
58. Hitomi Y, Ebisawa M, Tomikawa M, et al. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol 2009; 124:779-785; e776.
59. Wang CC, Fu CL, Yang YH, et al. Adenovirus expressing interleukin-1 receptor antagonist alleviates allergic airway inflammation in a murine model of asthma. Gene Ther 2006; 13:1414-1421.
60. Okada S, Inoue H, Yamauchi K, et al. Potential role of interleukin-1 in allergeninduced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 1995; 95:1236-1245.
61. Li T, Lu WL, Hong HY, et al. Pharmacokinetics and antiasthmatic potential of nonparenterally administered recombinant human interleukin-1 receptor antagonist in animal models. J Pharmacol Sci 2006; 102:321-330.
62. Johnson VJ, Yucesoy B, Luster MI. Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Allergy Clin Immunol 2005; 116:851-858.